Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5400MR)

This product GTTS-WQ5400MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5400MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11503MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ1976MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ6836MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ15669MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ5491MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ3002MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ8619MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ6412MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW